Featured Pharma Online Editorial

1. Why Supplier Diversification Doesn't Ensure Supply Safety 9/15/2026

   Recent events show supplier count to be an incomplete measure of resilience. The more useful question is whether separate supply arrangements remain independent when a critical material, capability, or route fails.

2. Can U.S. Policy Bring Generic Drug Manufacturing Back Home? 8/25/2026

   Generic medicines imported into the U.S. were not subject to the recently imposed tariffs on imported pharmaceuticals, but President Trump posted in July that this could change within two years.

3. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 8/7/2026

   Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

4. 6 Reasons Pharma Manufacturing Has Eyes On Puerto Rico 8/1/2026

   Several advantages explain why Puerto Rico continues to attract pharma investment, especially as manufacturers reassess supply chain risk and look for options closer to the U.S. mainland.

5. Bayer Adds A Spine To Modularity For Scale Without Disruption 7/16/2026

   Modular facility concepts offer a different path, giving manufacturers the ability to expand capacity stepwise, standardize core infrastructure, and adapt production environments as product portfolios evolve

6. Engineering Challenges In Designing Pharmaceutical Isolators 7/7/2026

   Designing pharmaceutical barrier systems requires balancing strict cleanliness with practical engineering. Explore key factors for optimizing airflow and ergonomics.

7. [VIDEO] GLP-1 Manufacturing's New Bottlenecks At Multi-Ton Scale 6/24/2026

   “At multi-ton scale, the challenge becomes less about making the molecule and more about controlling the variability of the process in this interconnected system,” explained Villain.

8. Can Molecular Glue Degraders Make The Undruggable Druggable? 6/12/2026

   Neomorph CEO Phil Chamberlain explains how molecular glue degraders could expand the druggable proteome and why the modality’s small-molecule profile may matter as much as its novel mechanism.

9. Chugai Accelerates Automation To Boost Operational Efficiency 6/3/2026

   What do you do when tasked with producing drugs of different molecular sizes, including highly potent compounds, in the same facility on a global scale? You tap technological advances in automation, modular design for flexibility, and tie it together with systems that enable real-time data.

10. The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process 6/2/2026

    Pharmaceutical continuous manufacturing is an enabler of better manufacturing, but only when implemented with intention.